108 patents
Page 2 of 6
Utility
Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
24 Jan 23
The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor.
Thuy-Anh Tran, Quyen-Quyen Do, Brett Ullman, Anthony C. Blackburn, Maiko Nagura
Filed: 14 Dec 20
Utility
Compounds useful in the treatment of autoimmune and inflammatory disorders
17 Jan 23
Abu J. M. Sadeque, Daniel J. Buzard
Filed: 5 Sep 19
Utility
Methods of Treating Conditions Related to the S1P1 Receptor
29 Dec 22
Provided are methods of treatment of eosinophilic GI diseases comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof.
Heather Kiyomi Komori-Occhicone, Thai Curtis Nguyen-Cleary, Jin Yu
Filed: 20 Nov 20
Utility
Compounds and methods for treatment of primary biliary cholangitis
27 Dec 22
The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(tri-fluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of primary biliary cholangitis (PBC).
Cheryl Geraldine Lassen, Robert Mark Jones, Que Liu, Ronald J. Christopher
Filed: 16 Feb 18
Utility
Modulators of the BETA-3 Adrenergic Receptor Useful for the Treatment or Prevention of Heart Failure and Disorders Related Thereto
15 Dec 22
Thuy-Anh Tran, Brett Ullman, Bryan Aubrey Kramer, Quyen-Quyen Thuy Do, Young-Jun Shin
Filed: 22 Apr 22
Utility
Substituted 3-PHENOXYAZETIDIN-1-YL-PYRAZINES
10 Nov 22
The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases.
Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
Filed: 29 Mar 21
Utility
Method of Treating Conditions Related to the PGI2 Receptor
10 Nov 22
Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.
Alan GLICKLICH
Filed: 12 Jul 22
Utility
Methods of Treating Conditions Related to the S1P1 Receptor
3 Nov 22
Provided are methods of treatment of Crohn's Disease comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)pbenzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Thai Curtis Nguyen-Cleary, Lisette Marie Acevedo
Filed: 30 Sep 20
Utility
Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
25 Oct 22
The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(triflu-oromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of extra-intestinal manifestations (EIM) in an individual with inflammatory bowel disease (BBD) and for the treatment of pyoderma gangrenosum (PG).
Cheryl Geraldine Lassen
Filed: 16 Feb 18
Utility
Cannabinoid Receptor Modulators
29 Sep 22
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor.
Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
Filed: 8 Nov 21
Utility
Method of treating conditions related to the PGI2 receptor
30 Aug 22
Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chloropbenyl)(pbenyl)carbamoyloxy)methyl)cyclohexyi)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.
Alan Glicklich
Filed: 12 Apr 21
Utility
Processes for the Preparation of (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC Acid and Salts Thereof
18 Aug 22
Antonio Garrido Montalban, Daniel J. Buzard, John A. DeMattei, Tawfik Gharbaoui, Stephen R. Johannsen, Ashwin M. Krishnan, Young Mi Kuhlman, You-An Ma, Michael John Martinelli, Suzanne Michiko Sato, Dipanjan Sengupta
Filed: 14 Sep 21
Utility
Cannabinoid Receptor Modulators
4 Aug 22
Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
Filed: 17 Sep 21
Utility
5-HT
26 Jul 22
Juerg Lehmann, Konrad Feichtinger, Albert S. Ren, Graeme Semple
Filed: 14 Apr 20
Utility
Composition of a 5-HT2A Serotonin Receptor Modulator Useful for the Treatment of Disorders Related Thereto
26 May 22
The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation.
Lee Alani Selvey, Marlon Carlos, Paul Maffuid, Yun Shan, William L. Betts, III, Deam Windate Given, III, Ryan M. Hart, Zezhi Jesse Shao
Filed: 1 Jul 21
Utility
Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto
24 May 22
Thuy-Anh Tran, Brett Ullman, Bryan Aubrey Kramer, Quyen-Quyen Thuy Do, Young-Jun Shin
Filed: 6 Dec 18
Utility
Methods of Treating Conditions Related to the S1P1 Receptor
12 May 22
Provided are methods for selecting individuals for treatment with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Snehal U. NAIK
Filed: 8 Jan 20
Utility
Methods of Treating Conditions Related to the S1P1 Receptor
27 Jan 22
Provided is a method of determining if an individual is a responder to treatment with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof.
Snehal U. Naik
Filed: 26 Nov 19
Utility
Crystalline L-arginine Salt of (R)-2-(7-(4-CYCLOPENTYL-3- (TRIFLUOROMETHYL)BENZYLOXY)-1,2,3, 4-TETRAHYDROCYCLO-PENTA [B]INDOL-3-YL)ACETIC ACID(COMPOUND1) for Use In Sipi Receptor-associated Disorders
6 Jan 22
The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).
Anthony C. Blackburn, Ryan O. Castro, Mark Allen Hadd, You-An Ma, Antonio Garrido Montalban, Jaimie Karyn Rueter, Lee Alani Selvey, Sagar Raj Shakya, Marlon Carlos
Filed: 14 Jul 21
Utility
Cannabinoid receptor modulators
4 Jan 22
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor.
Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
Filed: 24 Sep 19